Australia
· Delayed Price · Currency is AUD Acrux Company Description
Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream.
It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.
The company was incorporated in 1998 and is based in West Melbourne, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Michael Kotsanis |
Contact Details
Address: 103-113, Stanley Street West Melbourne, Victoria 3003 Australia | |
| Phone | 61 3 8379 0100 |
| Website | acrux.com.au |
Stock Details
| Ticker Symbol | ACR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ACR3 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | Chief Executive Officer, MD and Executive Director |
| Joanna Johnson B.E., BEc, ICAA | Chief Financial Officer and Company Secretary |